Search Within

Howard Scher

Formats
  1. Journal Article (626)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (7)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1133)
  2. Genitourinary Oncology Service (1133)
  3. Solid Tumor Oncology Division (1133)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (112)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (11)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1133)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transcriptional programs affected by androgen ablation therapy and the development of therapy resistant prostate cancer
    Meeting Abstract

    Lal, P.; Holzbeierlein, J.; LaTulippe, E.; Satagopan, J.; Smith, A.; Ryan, C.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.
    Modern Pathology (2003)

    Fulltext@MSK | Save
  • Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W. K.; O'connor, O.; Richon, V. M.; Curley, T.; Richardson, S.; Thapi, D.; Chiao, J. H.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Prostate carcinoma: Defining therapeutic objectives and improving overall outcomes
    Journal Article

    Scher, H. I.
    Cancer (2003)

    Fulltext@MSK | Save
  • Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center
    Journal Article

    Morris, M. J.; Scher, H. I.
    Critical Reviews in Oncology/Hematology (2003)

    Fulltext@MSK | Save
  • DNA vaccines: An active immunization strategy for prostate cancer
    Journal Article

    Wolchok, J. D.; Gregor, P. D.; Nordquist, L. T.; Slovin, S. F.; Scher, H. I.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save
  • Hsp90 as a therapeutic target in prostate cancer
    Journal Article

    Solit, D. B.; Scher, H. I.; Rosen, N.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save
  • Prostate cancer: A dynamic illness with shifting targets
    Journal Article

    Shaffer, D. R.; Scher, H. I.
    Lancet Oncology (2003)

    Fulltext@MSK | Save
  • Advances in imaging in the postoperative patient with a rising prostate-specific antigen level
    Journal Article

    Hricak, H.; Schòˆder, H.; Pucar, D.; Lis, E.; Eberhardt, S. C.; Onyebuchi, C. N.; Scher, H. I.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save
  • p27 as a target for cancer therapeutics
    Journal Article

    Blain, S. W.; Scher, H. I.; Cordon-Cardo, C.; Koff, A.
    Cancer Cell (2003)

    Fulltext@MSK | Save
  • Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial
    Journal Article

    Verbel, D. A.; Kelly, W. K.; Smaletz, O.; Regan, K.; Curley, T.; Heller, G.; Scher, H. I.
    Urology (2003)

    Fulltext@MSK | Save